A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

Summary

This study is to evaluate the safety and tolerability of EMB-09 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-09 will also be assessed.

Timeline

Start

2022-07-25

Primary completion

2023-12-31

Completion

2024-12-31

Drugs

Indications